SG11202109645QA - Methods of treating al amyloidosis - Google Patents
Methods of treating al amyloidosisInfo
- Publication number
- SG11202109645QA SG11202109645QA SG11202109645QA SG11202109645QA SG 11202109645Q A SG11202109645Q A SG 11202109645QA SG 11202109645Q A SG11202109645Q A SG 11202109645QA SG 11202109645Q A SG11202109645Q A SG 11202109645QA
- Authority
- SG
- Singapore
- Prior art keywords
- amyloidosis
- treating
- methods
- Prior art date
Links
- 208000023761 AL amyloidosis Diseases 0.000 title 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1124—Determining motor skills
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T15/00—3D [Three Dimensional] image rendering
- G06T15/06—Ray-tracing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T15/00—3D [Three Dimensional] image rendering
- G06T15/50—Lighting effects
- G06T15/506—Illumination models
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962814252P | 2019-03-05 | 2019-03-05 | |
US201962942722P | 2019-12-02 | 2019-12-02 | |
PCT/IB2020/000186 WO2020178638A1 (en) | 2019-03-05 | 2020-03-05 | Methods of treating al amyloidosis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202109645QA true SG11202109645QA (en) | 2021-10-28 |
Family
ID=70476256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202109645Q SG11202109645QA (en) | 2019-03-05 | 2020-03-05 | Methods of treating al amyloidosis |
Country Status (16)
Country | Link |
---|---|
US (2) | US11692024B2 (es) |
EP (1) | EP3934689A1 (es) |
JP (1) | JP2022522889A (es) |
KR (1) | KR20220019656A (es) |
CN (1) | CN113811332A (es) |
AU (1) | AU2020231081A1 (es) |
BR (1) | BR112021017550A2 (es) |
CA (1) | CA3132780A1 (es) |
CL (1) | CL2021002318A1 (es) |
FR (1) | FR3111560B1 (es) |
IL (1) | IL286040A (es) |
JO (1) | JOP20210245A1 (es) |
MA (1) | MA55209A (es) |
MX (1) | MX2021010665A (es) |
SG (1) | SG11202109645QA (es) |
WO (1) | WO2020178638A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3192069A1 (en) * | 2020-09-14 | 2022-03-17 | Michael Spector | Method of treating amyloidosis |
TW202332465A (zh) * | 2021-01-29 | 2023-08-16 | 愛爾蘭商普羅希那生物科學有限公司 | 治療al類澱粉變性症之方法 |
WO2023137342A2 (en) * | 2022-01-11 | 2023-07-20 | Prothena Biosciences Limited | Methods of treating al amyloidosis |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
EP3569610A3 (en) | 2000-12-12 | 2020-03-18 | Medlmmune, LLC | Molecules with extended half lives, compositions and uses thereof |
AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
DK2567976T3 (en) | 2005-03-23 | 2017-10-23 | Genmab As | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYLOMA |
DK2237803T3 (en) | 2007-12-28 | 2015-10-05 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
SG11201401360XA (en) | 2011-10-25 | 2014-05-29 | Onclave Therapeutics Ltd | Antibody formulations and methods |
KR101759694B1 (ko) | 2011-10-28 | 2017-07-19 | 인테그리티 바이오, 아이엔씨. | 아미노산을 함유하는 단백질 제제 |
EP3186273A4 (en) | 2014-08-26 | 2018-05-02 | University of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
KR102602754B1 (ko) | 2015-05-20 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체 |
KR20180067693A (ko) | 2015-11-03 | 2018-06-20 | 얀센 바이오테크 인코포레이티드 | 항-cd38 항체의 피하 제제 및 이의 용도 |
JP2019519584A (ja) * | 2016-06-30 | 2019-07-11 | プロシーナ バイオサイエンシーズ リミテッド | アミロイドーシスを処置するための組成物 |
US11382974B2 (en) * | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
US20200002410A1 (en) | 2018-06-28 | 2020-01-02 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
JOP20210220A1 (ar) | 2019-02-12 | 2023-01-30 | Prothena Biosciences Ltd | معالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي cd38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرى |
-
2020
- 2020-03-05 JP JP2021552586A patent/JP2022522889A/ja active Pending
- 2020-03-05 BR BR112021017550A patent/BR112021017550A2/pt unknown
- 2020-03-05 CA CA3132780A patent/CA3132780A1/en active Pending
- 2020-03-05 EP EP20722638.2A patent/EP3934689A1/en active Pending
- 2020-03-05 CN CN202080033593.5A patent/CN113811332A/zh active Pending
- 2020-03-05 JO JOP/2021/0245A patent/JOP20210245A1/ar unknown
- 2020-03-05 KR KR1020217031814A patent/KR20220019656A/ko unknown
- 2020-03-05 MA MA055209A patent/MA55209A/fr unknown
- 2020-03-05 AU AU2020231081A patent/AU2020231081A1/en active Pending
- 2020-03-05 MX MX2021010665A patent/MX2021010665A/es unknown
- 2020-03-05 WO PCT/IB2020/000186 patent/WO2020178638A1/en unknown
- 2020-03-05 US US16/810,319 patent/US11692024B2/en active Active
- 2020-03-05 SG SG11202109645Q patent/SG11202109645QA/en unknown
-
2021
- 2021-06-16 FR FR2106376A patent/FR3111560B1/fr active Active
- 2021-09-01 IL IL286040A patent/IL286040A/en unknown
- 2021-09-03 CL CL2021002318A patent/CL2021002318A1/es unknown
-
2023
- 2023-05-08 US US18/313,792 patent/US20230331831A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230331831A1 (en) | 2023-10-19 |
FR3111560A1 (fr) | 2021-12-24 |
MX2021010665A (es) | 2021-12-10 |
BR112021017550A2 (pt) | 2021-11-09 |
JP2022522889A (ja) | 2022-04-20 |
MA55209A (fr) | 2022-01-12 |
AU2020231081A1 (en) | 2021-09-30 |
US11692024B2 (en) | 2023-07-04 |
US20200308260A1 (en) | 2020-10-01 |
IL286040A (en) | 2021-10-31 |
CA3132780A1 (en) | 2020-09-10 |
KR20220019656A (ko) | 2022-02-17 |
CL2021002318A1 (es) | 2022-05-06 |
EP3934689A1 (en) | 2022-01-12 |
CN113811332A (zh) | 2021-12-17 |
FR3111560B1 (fr) | 2024-03-22 |
JOP20210245A1 (ar) | 2023-01-30 |
WO2020178638A1 (en) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280919A (en) | Methods for treating disorders related to aging | |
SG11202010830WA (en) | Methods of treating phenylketonuria | |
IL286040A (en) | Methods for treating amyloidosis | |
IL285110A (en) | Methods for treating multiple myeloma | |
IL288612A (en) | Treatments for angioedema | |
IL277379A (en) | Methods for treating TTR amyloidosis using AG10 | |
ZA202203776B (en) | Methods of treating epilepsy using the same | |
IL283337A (en) | Methods for treating whsc1-overexpressing cancers by inhibiting setd2 | |
IL278759A (en) | A method for treating clinical depression | |
SG11202112232YA (en) | Methods of treating neuropathy | |
IL292678A (en) | Methods for treating depressive disorders | |
SG11202107017TA (en) | Methods of treating cancer | |
IL287210A (en) | Preparations for the treatment of tumors | |
IL287130A (en) | Methods for treating itching | |
IL284797A (en) | Addiction treatment methods | |
IL285822A (en) | Methods for treating organic acidosis | |
SG11202105877YA (en) | Method of treatment | |
IL268111A (en) | Methods of treating pain | |
GB201907305D0 (en) | Treatment of conditions | |
IL304755A (en) | Treatment methods for amyloidosis | |
IL289824A (en) | Methods for treating multiple sclerosis | |
IL290983A (en) | Treatment methods | |
GB201918853D0 (en) | Methods of treatment | |
GB201900942D0 (en) | Methods of treatment | |
IL287250A (en) | Method of treatment |